| Literature DB >> 27775672 |
Tiago Torres1, Isabel Cunha2, Rosário Martins3,4, Miguel M Santos5,6.
Abstract
Recently, several emerging pollutants, including Personal Care Products (PCPs), have been detected in aquatic ecosystems, in the ng/L or µg/L range. Available toxicological data is limited, and, for certain PCPs, evidence indicates a potential risk for the environment. Hence, there is an urgent need to gather ecotoxicological data on PCPs as a proxy to improve risk assessment. Here, the toxicity of three different PCPs (4-Methylbenzylidene Camphor (4-MBC), propylparaben and triclocarban) was tested using embryo bioassays with Danio rerio (zebrafish) and Paracentrotus lividus (sea urchin). The No Observed Effect Concentration (NOEC) for triclocarban was 0.256 µg/L for sea urchin and 100 µg/L for zebrafish, whereas NOEC for 4-MBC was 0.32 µg/L for sea urchin and 50 µg/L for zebrafish. Both PCPs impacted embryo development at environmentally relevant concentrations. In comparison with triclocarban and 4-MBC, propylparaben was less toxic for both sea urchin (NOEC = 160 µg/L) and zebrafish (NOEC = 1000 µg/L). Overall, this study further demonstrates the sensitivity of embryo bioassays as a high-throughput approach for testing the toxicity of emerging pollutants.Entities:
Keywords: 4-Methylbenzylidene Camphor; Authorization; Evaluation; Registration; and Restriction of Chemicals (REACH); embryo bioassays; personal care products; propylparaben; risk assessment; sea urchin; triclocarban; zebrafish
Mesh:
Substances:
Year: 2016 PMID: 27775672 PMCID: PMC5085786 DOI: 10.3390/ijms17101762
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Effects of 4-Methylbenzylidene Camphor (4-MBC), propylparaben (PP) and triclocarban (TCC) exposures in Danio rerio. Controls and solvent controls were grouped. Significantly different results from controls (p < 0.05) are marked with a symbol (*). Data are expressed as mean ± SE (n = 16 for 4-MBC controls; n = 32 for propylparaben and triclocarban controls; n = 8 for exposed groups).
| Compound | Endpoints | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Treatment (µg/L) | Mortalitiy Rate | Hatching Rate | Abnormal Cellular Growth | 75%-Epiboly | Head Abnormalities | Eyes Abnormalities | Yolk-sac Abnormalities | Tail Abnormalities | Pericardial Edema | Heart Rate | Total Abnormalities | Abnormal Muscular Contractions | |
| 4-MBC | Controls | 1.88 ± 1.0 | 95.0 ± 1.58 | 1.25 ± 0.85 | 90.0 ± 6.26 | 1.04 ± 1.04 | 1.04 ± 1.04 | 1.04 ± 1.04 | 2.08 ± 1.42 | 1.04 ± 1.04 | 126.75 ± 4.46 | 2.08 ± 1.42 | 0.0 ± 0.0 |
| 5 | 7.5 ± 4.12 | 87.5 ± 3.66 | 7.5 ± 4.12 | 91.25 ± 3.98 | 4.17 ± 2.72 | 4.17 ± 2.72 | 4.17 ± 2.72 | 6.25 ± 3.05 | 2.08 ± 2.08 | 123.5 ± 3.58 | 6.25 ± 3.05 | 0.0 ± 0.0 | |
| 50 | 6.25 ± 2.63 | 92.5 ± 3.13 | 3.75 ± 2.63 | 95.0 ± 2.67 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 6.25 ± 4.38 | 0.0 ± 0.0 | 120.0 ± 4.21 | 6.25 ± 4.38 | 0.0 ± 0.0 | |
| 500 | 5.0 ± 2.67 | 81.25 ± 4.79 | 3.75 ± 1.82 | 92.5 ± 3.13 | 4.17 ± 2.72 | 4.17 ± 2.72 | 4.17 ± 2.72 | 10.42 ± 3.05 | 2.08 ± 2.08 | 121.0 ± 3.53 | 10.42 ± 3.05 | 35.42 ± 11.55 * | |
| 5000 | 2.5 ± 1.64 | 38.75 ± 7.66 * | 1.25 ± 1.25 | 92.5 ± 4.91 | 4.17 ± 2.72 | 2.08 ± 2.08 | 2.08 ± 2.08 | 8.33 ± 4.45 | 2.08 ± 2.08 | 95.0 ± 3.0 * | 10.42 ± 4.38 | 85.42 ± 3.78 * | |
| PP | Controls | 3.13 ± 0.95 | 92.19 ± 1.89 | 1.56 ± 0.65 | 97.81 ± 0.74 | 1.56 ± 0.87 | 1.56 ± 0.87 | 1.56 ± 0.87 | 3.13 ± 1.17 | 2.08 ± 0.99 | 143.0 ± 2.02 | 3.13 ± 1.17 | – |
| 10 | 2.5 ± 1.64 | 87.5 ± 4.11 | 1.25 ± 1.25 | 96.25 ± 1.83 | 2.08 ± 2.08 | 2.08 ± 2.08 | 2.08 ± 2.08 | 2.08 ± 2.08 | 2.08 ± 2.08 | 144 ± 5.01 | 2.08 ± 2.08 | – | |
| 100 | 1.25 ± 1.25 | 90.0 ± 3.78 | 1.25 ± 1.25 | 98.75 ± 1.25 | 0.0 ± 0.0 | 0.0 ± 0.0 | 2.08 ± 2.08 | 0.0 ± 0.0 | 2.08 ± 2.08 | 146.0 ± 3.38 | 2.08 ± 2.08 | – | |
| 1000 | 4.37 ± 1.57 | 85.68 ± 5.91 | 1.25 ± 0.85 | 94.49 ± 1.76 | 3.13 ± 1.68 | 2.08 ± 1.42 | 2.08 ± 1.42 | 2.08 ± 1.42 | 2.08 ± 1.42 | 139.75 ± 3.36 | 4.17 ± 1.86 | – | |
| 3500 | 3.75 ± 1.83 | 66.25 ± 8.22 | 1.25 ± 1.25 | 96.25 ± 1.82 | 95.83 ± 2.73 * | 89.58 ± 5.4 * | 58.33 ± 7.04 * | 91.67 ± 3.15 * | 91.67 ± 4.45 * | 124.5 ± 6.16 * | 100 ± 0.0 * | – | |
| 6000 | 1.25 ± 1.25 | 18.75 ± 3.98 * | 1.25 ± 1.25 | 91.25 ± 3.98 | 100 ± 0.0 * | 95.83 ± 4.17 * | 83.33 ± 8.33 * | 93.75 ± 6.25 * | 100 ± 0.0 * | 67.5 ± 7.98 * | 100 ± 0.0 * | – | |
| 8500 | 21.25 ± 7.89 | 2.5 ± 2.5 * | 1.25 ± 1.25 | 87.5 ± 4.53 * | 100 ± 0.0 * | 100 ± 0.0 * | 100 ± 0.0 * | 100 ± 0.0 * | 100 ± 0.0 * | 70.29 ± 6.47 * | 100 ± 0.0 * | – | |
| 10,000 | 100 ± 0.0 * | 0.0 ± 0.0 * | 0.0 ± 0.0 | 87.5 ± 3.13 * | – | – | – | – | – | – | – | – | |
| TCC | Controls | 2.19 ± 0.87 | 96.88 ± 0.95 | 1.56 ± 0.79 | 97.81 ± 0.87 | 0.52 ± 0.52 | 0.52 ± 0.52 | 0.0 ± 0.0 | 0.0 ± 0.0 | 1.58 ± 0.88 | 130.5 ± 3.53 | 0.52 ± 0.52 | – |
| 10 | 1.25 ± 1.25 | 98.75 ± 1.25 | 1.25 ± 1.25 | 98.75 ± 1.25 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 4.25 ± 2.78 | 118.5 ± 4.07 | 0.0 ± 0.0 | – | |
| 100 | 6.25 ± 1.8 | 91.11 ± 2.26 | 1.68 ± 1.01 | 93.61 ± 2.08 | 2.08 ± 1.42 | 2.08 ± 1.42 | 2.08 ± 1.42 | 3.12 ± 1.68 | 4.23 ± 1.89 | 128.0 ± 4.29 | 3.13 ± 1.68 | – | |
| 350 | 75.0 ± 12.81 * | 91.25 ± 4.79 | 0.0 ± 0.0 | 97.5 ± 1.64 | 5.56 ± 5.56 | 0.0 ± 0.0 | 0.0 ± 0.0 | 33.33 ± 33.33 | 0.0 ± 0.0 | 72.0 ± 48.0 | 33.33 ± 33.33 | – | |
| 600 | 95.0 ± 5.0 * | 92.5 ± 3.66 | 1.25 ± 1.25 | 97.5 ± 1.64 | 0.0 ± 0.0 | 0.0 ± 0.0 | 0.0 ± 0.0 | 16.67 ± 16.67 | 0.0 ± 0.0 | – | 16.67 ± 16.67 | – | |
| 850 | 100 ± 0.0 * | 93.75 ± 2.63 | 1.25 ± 1.25 | 98.75 ± 1.25 | – | – | – | – | – | – | – | – | |
| 1000 | 100 ± 0.0 * | 95.0 ± 2.76 | 0.0 ± 0.0 | 100 ± 00 | – | – | – | – | – | – | – | – | |
| 10,000 | 100 ± 0.0 * | 83.75 ± 5.32 | 0.0 ± 0.0 | 98.75 ± 1.25 | – | – | – | – | – | – | – | – | |
Figure 1Larval length (%) and total abnormalities (%) of Paracentrotus lividus exposed to different concentrations of 4-Methylbenzylidene Camphor (4-MBC) (A), propylparaben (PP) (B), and triclocarban (TCC) (C) for 48 h. Controls and solvent controls were grouped. Results of first and second assays are normalized to the respective control assay, for both endpoints. Bars with the letter (a) or the symbol (*) indicate significant differences from controls (p < 0.05). The percentage of larval length inhibition data are expressed as mean ± SE (n = 480 for controls; n = 240 for 5 µg/L 4-MBC, 1000 µg/L PP, 10 µg/L TCC and 0.64 µg/L TCC; n = 120 for the other groups). The percentage of total abnormalities data are expressed as mean ± SE (n = 32 for controls; n = 16 for 5 µg/L 4-MBC, 1000 µg/L PP, 10 µg/L TCC and 0.64 µg/L TCC; n = 8 for the other groups).
Comparison of NOEC and LOEC values of selected PCPs reported in this study. Maximal concentrations of selected PCPs detected in surface water and in WWTPs influents and effluents (µg/L) retrieved from the literature.
| Compound | Zebrafish | Sea Urchin | Maximal Concentration | ||||
|---|---|---|---|---|---|---|---|
| – | |||||||
| 4-MBC | 50 | 500 | 0.32 | 0.8 | 6.5 [ | 2.7 [ | * 0.799 [ |
| PP | 1000 | 3500 | 160 | 400 | 2.8 [ | 0.021[ | 0.207 [ |
| TCC | 100 | 350 | 0.256 | 0.64 | 50 [ | >10 [ | 6.75 [ |
No Observed Effect Concentration (NOEC), Lowest Observed Effect Concentration (LOEC), Personal Care Products (PCPs), Wastewater Treatment Plans (WWTPs); * coastal areas.
Tested concentrations in zebrafish and sea urchin exposures (µg/L).
| Zebrafish | Sea Urchin | ||||
|---|---|---|---|---|---|
| 4-MBC | PP | TCC | 4-MBC | PP | TCC |
| 5000 | 10,000 | 10,000 | 5000 | 10,000 | 10,000 |
| 500 | 8500 | 1000 | 500 | 1000 | 1000 |
| 50 | 6000 | 850 | 50 | 400 | 100 |
| 5 | 3500 | 600 | 5 | 160 | 10 |
| – | 1000 | 350 | 2 | 100 | 4 |
| – | 100 | 100 | 0.8 | 64 | 1.6 |
| – | 10 | 10 | 0.32 | 10 | 0.64 |
| – | – | – | – | – | 0.256 |
| – | – | – | – | – | 0.1024 |
Endpoints recorded at 8, 32 and 80 hpf in Danio rerio bioassay.
| Endpoint | 8 hpf | 32 hpf | 80 hpf |
|---|---|---|---|
| Mortality rate | ✓ | ✓ | ✓ |
| 75% of epiboly stage | ✓ | – | – |
| Abnormal cell growth | ✓ | – | – |
| Head abnormalities | – | ✓ | ✓ |
| Tail abnormalities | – | ✓ | ✓ |
| Eyes abnormalities | – | ✓ | ✓ |
| Yolk-sac abnormalities | – | ✓ | ✓ |
| Pericardial edema | – | ✓ | ✓ |
| Heart rate | – | ✓ | ✓ |
| Hatching rate | – | – | ✓ |
| (1) Muscular involuntary contractions | – | – | ✓ |
(1) Only detected for 4-MBC exposure.
Figure 2Embryonic stages and developmental abnormalities of the sea urchin Paracentrotus lividus observed in this study after 48 h of incubation under controlled conditions of temperature and light: (A) normal larva at pluteus stage; (B) gastrula stage; (C) prism larvae; (D) separated tip; (E,F) crossed tip; (F,G) fused arms; (G) general abnormal larvae; (H,I) abnormal arms orientation; (J) deformed arms; (K) arms absence; and (K,L) asymmetric arms.